Switch to LPV/r monotherapy
HIV-NAT 077 Study: Switch double PI/r to LPV/r monotherapy
Original article : AIDS. 2011 Jan 28;25(3):315-23 – T Bunupuradah
Last update :
28/03/2014
Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK
- Simplifying second-line treatment from double-boosted PI therapy to LPV/r monotherapy allows for sustain virologic suppression in the majority of children after 48 weeks of follow-up
- 50 HIV-1 infected Thaï children failing first line NRTIs + NNRTI, switched to double ritonavir-boosted PIs for 144 weeks (LPV/r + SQV = 90%) ; 40 children with virological suppression (HIV-1 RNA < 50 c/mL at least 3 months apart) switched to LPV/r 230/57.5 mg/m2 bid monotherapy
- Female: 50%, Median age: 11.7 years
- At W48
- HIV-1 RNA < 50 c/mL: 72.5%
- Still on LPV/r monotherapy, N = 31 (78%)
- Returned to double boosted PIs due to failure, N = 9
- No emergence of major protease resistance mutations
Back to Table of Contents
Download the slides
